Overcoming therapeutic resistance in driver-negative NSCLC: Immunomodulatory mechanisms and clinical efficacy of Camrelizumab-chemotherapy combination in a real-world cohort

Abstract Background Driver gene-negative advanced non-squamous non-small cell lung cancer (NSCLC) exhibits inherent resistance to conventional therapies, representing a significant treatment challenge. The limited efficacy of platinum-based chemotherapy alone underscores the need for resistance-miti...

Full description

Bibliographic Details
Published in:	Discover Oncology
Main Authors:	Yan Ge, Yang Zhao
Format:	Article
Language:	English
Published:	Springer 2025-06-01
Subjects:	NSCLC Camrelizumab Treatment resistance Immunomodulation PD-1 Inhibition Chemoimmunotherapy
Online Access:	https://doi.org/10.1007/s12672-025-02926-0

Similar Items

Analysis of the efficacy and safety of camrelizumab combined with chemotherapy for cervical cancer treatment
by: Song-Tian Yang, et al.
Published: (2025-02-01)

Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland
by: Xiaoting Liu, et al.
Published: (2024-07-01)

Efficacy of Combination of Camrelizumab with Anlotinib as Third-line Therapy for Patients with Advanced Non-small Cell Lung Cancer
by: ZHANG Xiaojuan, et al.
Published: (2023-06-01)

Efficacy and safety of camrelizumab for the treatment of cervical cancer: a systematic review and meta-analysis
by: Xiaodong Mi, et al.
Published: (2024-12-01)

Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study
by: Li Zhou, et al.
Published: (2022-05-01)

Combining nanoparticle albumin-bound paclitaxel with camrelizumab in advanced soft tissue sarcoma: activity, safety, and future perspectives
by: Zhichao Tian, et al.
Published: (2024-02-01)

Development of an LC–TOF/MS Method to Quantify Camrelizumab in Human Serum
by: Li Song, et al.
Published: (2024-10-01)

Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma
by: Pingyu Chen, et al.
Published: (2024-05-01)

Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China
by: Hongbin Dai, et al.
Published: (2023-02-01)

Camrelizumab as a novel third or post-third-line treatment strategy in small cell lung cancer: a retrospective study of 12 patients
by: Jizheng Tian, et al.
Published: (2023-07-01)

Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, KEAP1/STK11 co-mutated metastatic NSCLC
by: Nicolas Roussot, et al.
Published: (2024-08-01)

Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
by: Xin Li, et al.
Published: (2022-09-01)

Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)
by: Belén Sierra Rodero, et al.
Published: (2025-12-01)

Antibiotic Use and Survival in Patients With Late-Stage NSCLC Treated With Chemoimmunotherapy
by: Emanuela Taioli, MD, PhD, et al.
Published: (2024-12-01)

Psoriasis caused by camrelizumab in a patient with esophageal cancer: a case report
by: Yimei Duan, et al.
Published: (2025-10-01)

Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab
by: Wenling Ye, et al.
Published: (2023-07-01)

Successful treatment of recurrent sarcomatous choledochal carcinoma with camrelizumab and apatinib
by: Shilei Li
Published: (2023-11-01)

Clinical efficacy of Camrelizumab combined with first-line chemotherapy in extensive-stage small-cell lung cancer
by: Dou Zhang, et al.
Published: (2024-01-01)

Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study
by: Yanfei Liu, et al.
Published: (2023-04-01)

Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma
by: Zhou WJ, et al.
Published: (2024-12-01)

Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 studyResearch in context
by: Xi Ding, et al.
Published: (2023-07-01)

Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial
by: Shuyu Ji, et al.
Published: (2025-07-01)

Camrelizumab combined with chemotherapy for stage IV pulmonary sarcomatoid cancer with pancreatic metastases
by: Liqin Ruan, et al.
Published: (2024-01-01)

Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study
by: Wencheng Zhang, et al.
Published: (2021-01-01)

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
by: Qingyuan Zhang, et al.
Published: (2022-10-01)

Prognostic Value of Alpha-Fetoprotein in Unresectable Hepatocellular Carcinoma Treated with Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab
by: Xiao Y, et al.
Published: (2024-07-01)

Transcatheter arterial chemoembolization of apatinib and camrelizumab (SHR1210) against liver metastasis from hepatic neuroendocrine tumor: a case report
by: Ruobing Qi, et al.
Published: (2024-02-01)

Monotherapy of PD-1 Inhibitor Camrelizumab Reverses Advanced Lung Squamous Cell Carcinoma with Low PD-1 Expression: A Case Report
by: Xiufen Zheng, et al.
Published: (2024-08-01)

Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy
by: Zheng X, et al.
Published: (2025-06-01)

Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer
by: Yang Ge, et al.
Published: (2023-04-01)

RETRACTED: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
by: Qing Yang, et al.
Published: (2023-03-01)

Long survival after neoadjuvant and adjuvant camrelizumab plus chemotherapy and surgery in a patient with hepatoid adenocarcinoma of the lung: A case report
by: Xuhua Huang, et al.
Published: (2024-12-01)

Prognostic Value of KRAS/TP53 Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief Report
by: Vincent D. de Jager, MD, et al.
Published: (2024-12-01)

An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma
by: Yunqian Chu, et al.
Published: (2024-08-01)

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial
by: Yanfei Liu, et al.
Published: (2024-03-01)

Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study
by: Qi Zhao, et al.
Published: (2025-08-01)

Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review
by: Huifang Lv, et al.
Published: (2023-01-01)

A multicenter, real‐world study on effectiveness and safety of first‐line modified PD‐1 inhibitors with chemotherapy in advanced non‐small cell lung cancer (aNSCLC) with drive gene‐negative
by: Tao Li, et al.
Published: (2024-02-01)

Use of camrelizumab in treatment of nasopharyngeal carcinoma
by: Yu. V. Alymov, et al.
Published: (2024-12-01)

Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
by: Yinfang Gu, et al.
Published: (2025-02-01)